Aldose reductase inhibitor, fidarestat prevents high-fat diet-induced intestinal polyps in APCmin/+ mice

Ashish Saxena, Ravinder Tammali, Kota Ramana, Satish Srivastava

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Recent epidemiological and experimental studies have shown that obesity is a major risk factor for Colorectal Cancer (CRC). Regular intake of high fat-containing diet can promote obesity and metabolic syndrome by increasing the insulin resistance and inflammatory response which contribute to carcinogenesis. Previously, we have shown that inhibition of polyol pathway enzyme aldose reductase (AR) prevents carcinogens-and inflammatory growth factors-induced CRC. However, the effect of AR inhibition on a high-fat diet (HFD)-induced formation of intestinal polyps in Apc-deficient Min (multiple intestinal neoplasia; ApcMin/+) mice is not known. Methods: We examined the effect of AR inhibitor, fidarestat on the HFD-induced formation of preneoplastic intestinal polyps in ApcMin/+ mice which is an excellent model of colon cancer. Results: APCMin/+ mice fed for 12 weeks of HFD caused a significant increase in the formation of polyps in the small and large intestines and fidarestat given along with the HFD prevented the number of intestinal polyps. Fidarestat also decreased the size of the polyps in the intestines of HFD-treated APC Min mice. Further, the expression levels of beta-catenin, PCNA, PKC-β2, P-AKT, P-p65, COX-2, and iNOS in the small and large intestines of HFD-treated mice significantly increased, and AR inhibitor prevented it. Conclusion: Our results thus suggest that fidarestat could be used as a potential chemopreventive drug for intestinal cancers due to APC gene mutations.

Original languageEnglish (US)
Pages (from-to)905-911
Number of pages7
JournalCurrent Cancer Drug Targets
Volume18
Issue number9
DOIs
StatePublished - Jan 1 2018

Fingerprint

Intestinal Polyps
Aldehyde Reductase
High Fat Diet
Large Intestine
Polyps
Small Intestine
Colorectal Neoplasms
Obesity
APC Genes
Intestinal Neoplasms
Proliferating Cell Nuclear Antigen
beta Catenin
fidarestat
Carcinogens
Colonic Neoplasms
Intestines
Insulin Resistance
Epidemiologic Studies
Intercellular Signaling Peptides and Proteins
Carcinogenesis

Keywords

  • Aldose reductase
  • APC min mice
  • Colon cancer
  • Fidarestat
  • High-fat diet
  • Polyps

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Drug Discovery
  • Cancer Research

Cite this

Aldose reductase inhibitor, fidarestat prevents high-fat diet-induced intestinal polyps in APCmin/+ mice. / Saxena, Ashish; Tammali, Ravinder; Ramana, Kota; Srivastava, Satish.

In: Current Cancer Drug Targets, Vol. 18, No. 9, 01.01.2018, p. 905-911.

Research output: Contribution to journalArticle

Saxena, Ashish ; Tammali, Ravinder ; Ramana, Kota ; Srivastava, Satish. / Aldose reductase inhibitor, fidarestat prevents high-fat diet-induced intestinal polyps in APCmin/+ mice. In: Current Cancer Drug Targets. 2018 ; Vol. 18, No. 9. pp. 905-911.
@article{e7736696a6854a59814619b660e5720f,
title = "Aldose reductase inhibitor, fidarestat prevents high-fat diet-induced intestinal polyps in APCmin/+ mice",
abstract = "Background: Recent epidemiological and experimental studies have shown that obesity is a major risk factor for Colorectal Cancer (CRC). Regular intake of high fat-containing diet can promote obesity and metabolic syndrome by increasing the insulin resistance and inflammatory response which contribute to carcinogenesis. Previously, we have shown that inhibition of polyol pathway enzyme aldose reductase (AR) prevents carcinogens-and inflammatory growth factors-induced CRC. However, the effect of AR inhibition on a high-fat diet (HFD)-induced formation of intestinal polyps in Apc-deficient Min (multiple intestinal neoplasia; ApcMin/+) mice is not known. Methods: We examined the effect of AR inhibitor, fidarestat on the HFD-induced formation of preneoplastic intestinal polyps in ApcMin/+ mice which is an excellent model of colon cancer. Results: APCMin/+ mice fed for 12 weeks of HFD caused a significant increase in the formation of polyps in the small and large intestines and fidarestat given along with the HFD prevented the number of intestinal polyps. Fidarestat also decreased the size of the polyps in the intestines of HFD-treated APC Min mice. Further, the expression levels of beta-catenin, PCNA, PKC-β2, P-AKT, P-p65, COX-2, and iNOS in the small and large intestines of HFD-treated mice significantly increased, and AR inhibitor prevented it. Conclusion: Our results thus suggest that fidarestat could be used as a potential chemopreventive drug for intestinal cancers due to APC gene mutations.",
keywords = "Aldose reductase, APC min mice, Colon cancer, Fidarestat, High-fat diet, Polyps",
author = "Ashish Saxena and Ravinder Tammali and Kota Ramana and Satish Srivastava",
year = "2018",
month = "1",
day = "1",
doi = "10.2174/1568009617666170808105633",
language = "English (US)",
volume = "18",
pages = "905--911",
journal = "Current Cancer Drug Targets",
issn = "1568-0096",
publisher = "Bentham Science Publishers B.V.",
number = "9",

}

TY - JOUR

T1 - Aldose reductase inhibitor, fidarestat prevents high-fat diet-induced intestinal polyps in APCmin/+ mice

AU - Saxena, Ashish

AU - Tammali, Ravinder

AU - Ramana, Kota

AU - Srivastava, Satish

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Recent epidemiological and experimental studies have shown that obesity is a major risk factor for Colorectal Cancer (CRC). Regular intake of high fat-containing diet can promote obesity and metabolic syndrome by increasing the insulin resistance and inflammatory response which contribute to carcinogenesis. Previously, we have shown that inhibition of polyol pathway enzyme aldose reductase (AR) prevents carcinogens-and inflammatory growth factors-induced CRC. However, the effect of AR inhibition on a high-fat diet (HFD)-induced formation of intestinal polyps in Apc-deficient Min (multiple intestinal neoplasia; ApcMin/+) mice is not known. Methods: We examined the effect of AR inhibitor, fidarestat on the HFD-induced formation of preneoplastic intestinal polyps in ApcMin/+ mice which is an excellent model of colon cancer. Results: APCMin/+ mice fed for 12 weeks of HFD caused a significant increase in the formation of polyps in the small and large intestines and fidarestat given along with the HFD prevented the number of intestinal polyps. Fidarestat also decreased the size of the polyps in the intestines of HFD-treated APC Min mice. Further, the expression levels of beta-catenin, PCNA, PKC-β2, P-AKT, P-p65, COX-2, and iNOS in the small and large intestines of HFD-treated mice significantly increased, and AR inhibitor prevented it. Conclusion: Our results thus suggest that fidarestat could be used as a potential chemopreventive drug for intestinal cancers due to APC gene mutations.

AB - Background: Recent epidemiological and experimental studies have shown that obesity is a major risk factor for Colorectal Cancer (CRC). Regular intake of high fat-containing diet can promote obesity and metabolic syndrome by increasing the insulin resistance and inflammatory response which contribute to carcinogenesis. Previously, we have shown that inhibition of polyol pathway enzyme aldose reductase (AR) prevents carcinogens-and inflammatory growth factors-induced CRC. However, the effect of AR inhibition on a high-fat diet (HFD)-induced formation of intestinal polyps in Apc-deficient Min (multiple intestinal neoplasia; ApcMin/+) mice is not known. Methods: We examined the effect of AR inhibitor, fidarestat on the HFD-induced formation of preneoplastic intestinal polyps in ApcMin/+ mice which is an excellent model of colon cancer. Results: APCMin/+ mice fed for 12 weeks of HFD caused a significant increase in the formation of polyps in the small and large intestines and fidarestat given along with the HFD prevented the number of intestinal polyps. Fidarestat also decreased the size of the polyps in the intestines of HFD-treated APC Min mice. Further, the expression levels of beta-catenin, PCNA, PKC-β2, P-AKT, P-p65, COX-2, and iNOS in the small and large intestines of HFD-treated mice significantly increased, and AR inhibitor prevented it. Conclusion: Our results thus suggest that fidarestat could be used as a potential chemopreventive drug for intestinal cancers due to APC gene mutations.

KW - Aldose reductase

KW - APC min mice

KW - Colon cancer

KW - Fidarestat

KW - High-fat diet

KW - Polyps

UR - http://www.scopus.com/inward/record.url?scp=85057281118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057281118&partnerID=8YFLogxK

U2 - 10.2174/1568009617666170808105633

DO - 10.2174/1568009617666170808105633

M3 - Article

C2 - 28786349

AN - SCOPUS:85057281118

VL - 18

SP - 905

EP - 911

JO - Current Cancer Drug Targets

JF - Current Cancer Drug Targets

SN - 1568-0096

IS - 9

ER -